AHCC Nutrients USA
Dr Tanno Website
The results of medical research are usually revealed to the public and to other medical professionals in articles written for medical journals, or in papers presented at medical conferences by the doctors who conducted the research. Abstracts are summaries of the articles and papers. The following abstracts are representative of the many articles and papers written about the effects of AHCC.
Preventive Effect of Active Hexose Correlated Compound (AHCC) on the Recurrence of Postoperative Hepatocellular Carcinoma Patients H. Kitade, Y. Matsui, S. Takai, A. Imamura, Y. Kawaguchi, Y. Kamiyama, B. Sun, K. Kosuna Osaka/Sapporo, Japan
Many attempts have been made to stimulate the immune system for cancer treatment. Although several biological response modifiers have been developed such as BCG. Picibanil. PSK, interferon and interIeukin-2, the clinical efficacy of the substances has not been clearly elucidated. Active Hexose Correlated Compound (AHCC) is a newly developed biological response modifier. It is an extract of Basidiomycetes which is obtained by hybridization or several types of mushrooms. This study was initiated to evaluate the preventive effect of AHCC on the recurrence of hepatocellular carcinoma patients after surgical treatment.

In this study, 121 patients with histologically proven hepatocellular carcinoma were included. All of the patients underwent macroscopically curative resection of a 1iver tumor. In 38 patients, AHCC (3-6g/day) was administered orally after surgery (group A) and 18 patients began to take AHCC after recurrences were verified (group B). The other 65 patients served as controls (group C). The longest follow up periods were 39, 65 and 56 months for groups A, B and C respectively.

There were no significant differences between the three groups in the distribution of age, gender, clinical stage, hepatitis type B and/or C viral infection, amount of bleeding during surgery and resection volumes of the liver. The survival rate in group A was significantly higher than that in group C. The disease-free survival rate in group A was also significantly higher than that in groups B and C. One year after surgery, the serum levels of tumor markers (a.fetoprotein and PIVKA II) in group A were significantly lower than those in groups Band C.

This retrospective study suggests that AHCC intake has a preventive effect in postoperative hepatocellular carcinoma patients. Further detailed studies are needed to elucidate the mechanism of the effect of AHCC.

Home | Next Page: More Abstracts | Case Studies